All Posts Tagged With: "CTIC"
(CTIC) Cell Therapeutics Incorporated – Bull of the Day
In late September, Cell Therapeutics (CTIC) announced that a second independent radiologic review of data from the pivotal trial PIX301 of lead drug pixantrone for aggressive NHL confirmed the statistical...
(CTIC) Cell Therapeutics Quarterly Earnings Lag – Company Pares Loss
Cell Therapeutics (CTIC) suffered a net loss of 14 cents per share in the second quarter of 2011, compared with a net loss of 46 cents (excluding special items) per share in the year-ago quarter. The narrower...
(CPO) Company News for July 01, 2011 – Corporate Summary
• Shares of Cell Therapeutics, Inc. (NASDAQ:CTIC) declined by 19.64% after the cancer drug developer said it was selling Series 13 preferred stock worth $30 million
• Vitamin maker USANA Health Sciences...
(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares
We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25.
Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer....
(CTIC) Cell Therapeutics Posts Positive Pixantrone Data
Cell Therapeutics Inc. (CTIC) recently announced that data from an early stage study of its lead pipeline candidate, pixantrone, for an additional indication, was published in Cancer, an online journal.
The...
(CTIC) Cell Therapeutics Set to Resubmit Pixantrone NDA
Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug application...
(HNAB) Hana Bioscience Encouraging Phase II Results
Written by Grant Zeng, CFA
Hana Biosciences Inc. ( HNAB ) A decent pipeline with late stage candidates…
South San Francisco, CA based Hana Biosciences, Inc....
(CTIC) Cell Therapeutics Reports Narrower Third Quarter Loss
Cell Therapeutics Inc. (CTIC) suffered a net loss of $15.6 million (2 cents per share) in the third quarter of 2010 as opposed to the net loss of $48.8 million (9 cents per share) suffered in the year-ago...
(CTIC) Cell Therapeutics Analyst Cuts Shares to Underperform
We are downgrading Cell Therapeutics, Inc. (
7Oct2010 | vitalstocks | 0 comments | Continued(CTIC) Cell Therapeutics – Bear of the Day
We are downgrading Cell Therapeutics (CTIC) to Underperform from Neutral, primarily due to the uncertainty surrounding the approval of its lead candidate, pixantrone for aggressive NHL in the US.
Cell...
(CTIC) Cell Therapeutics Announces Challenge to US Food and Drug Administration Decision
Recently, Cell Therapeutics Inc. (CTIC) announced that it will appeal against the decision of the US Food and Drug Administration (FDA) to deny approval to the company’s lead candidate,...
(CTIC) Cell Therapeutics Stock Issuance Dilutes Shareholder Value
Cell Therapeutics (CTIC) recently decided to exchange up to 60 million shares of its common stock for $30 million of notes. Liquidity crisis at the company continues to remain a major concern for us. Earlier,...
(CTIC) Cell Therapeutics Announces Workforce Reduction
Cell Therapeutics (CTIC) recently reduced its workforce by 36 employees. The reduction in staff strength along with the elimination of other planned expenses is likely to result in savings of about $16 million...
(CTIC) Cell Therapeutics’ Pixantrone Denied FDA Approval
In a major setback, Cell Therapeutics (CTIC) has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for Pixuvri (pixantrone dimaleate). The company has been seeking approval...
(CTIC) Cell Therapeutics Seeks FDA Approval of non-Hodgkin’s Lymphoma Candidate
April is crucial for Cell Therapeutics (CTIC), as the US Food and Drug Administration (FDA) decides on the approvability of pixantrone by April 23, 2010. The company is seeking approval of its lead candidate,...
(CTIC) Cell Therapeutics Suffers as FDA Panel Rules Against Pixantrone
In a major disappointment for Cell Therapeutics’ (CTIC), the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee unanimously decided against the approval of the company’s...
(CTIC) Cell Therapeutics Gets Good News From the FDA
In a positive development, Cell Therapeutics (CTIC) announced that the US Food and Drug Administration (FDA) has completed its inspection of the company’s manufacturing facility in Italy and found it to...
(CTIC) Cell Therapeutics’ Drug Approval Delayed
The wait for the approval of Cell Therapeutics’ (CTIC) drug, Pixuvri (pixantrone) is far from over. Recently, the US Food and Drug Administration (FDA) announced that the Oncologic Drugs Advisory Committee...
(CTIC) Cell Therapeutics Guards Againt Hostile Takeover
In an attempt to guard itself against hostile takeover, Cell Therapeutics (CTIC) adopted a shareholder rights plan. The plan, to be effective from Jan 7, 2010, has been designed so that a potential buyer...
(CTIC) Cell Therapeutics Reports Positive Data
Cell Therapeutics (CTIC) announced positive data from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone in relapsed or refractory, aggressive non-Hodgkin’s lymphoma (NHL) patients...
(CTIC) Cell Therapeutics Reports Earnings – Awaiting FDA Decision
Cell Therapeutics’ (CTIC) third quarter loss per share came in at 8 cents compared to a loss of $1.14 reported in the year ago period. The company does not have any marketed product at...
(CTIC) Cell Therapeutics Releases Encouraging Data for Pixantrone
Yesterday, Cell Therapeutics (CTIC) released encouraging data from the 18-month follow-up clinical trial of pixantrone for the treatment of patients with advanced, relapsed or refractory, aggressive non-Hodgkin’s lymphoma (NHL).
The original trial...
(CTIC) Cell Therapeutics Fails to Impress
We were disappointed to hear that the US Food and Drug Administration (FDA) has granted standard review status to Cell Therapeutics’ (CTIC) pixantrone for the treatment of relapsed and refractory non-Hodgkin’s lymphoma (NHL).
The company...
(NVS) Novartis Ends NSCLC Drug Enrollment
Yesterday, patient enrollment (1200) for a phase III trial of ASA404, jointly developed by Novartis (NVS) and Antisoma for the treatment of non small-cell lung cancer (NSCLC) was completed. Novartis is conducting the trial as the development and commercialization...
(CTIC) Cell Therapeutics’ Drug Accepted For Review at FDA
We are pleased to hear that the US Food and Drug Administration (FDA) accepted and filed for review Cell Therapeutics’ (CTIC) New Drug Application (NDA). The company is seeking FDA approval (NDA filed in June 2009) for pixantrone for the treatment of relapsed...